Patent classifications
C
CHEMISTRY; METALLURGY
Load children
C07
ORGANIC CHEMISTRY
Load children
C07D
HETEROCYCLIC COMPOUNDS
Load children
455/00
Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
Load children Filter patents View analytics View as hierarchy Open in page
C07D455/03
containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
Load children Filter patents View analytics View as hierarchy Open in page
C07D455/04
containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
Load children Filter patents View analytics View as hierarchy Open in page
C07D455/06
containing benzo [a] quinolizine ring systems
Load children Filter patents View analytics View as hierarchy Open in page
C07D455/08
having an isoquinolyl-1, a substituted isoquinolyl-1 or an alkylenedioxyisoquinolyl-1 radical linked through only one carbon atom, attached in position 2, e.g. emetine
Filter patents View analytics View as hierarchy Open in page

C07D455/08

FUSED RING COMPOUND
20250282774 · 2025-09-11 · ·

The present invention relates to a fused ring compound; specifically, provided in the present invention is the use of a compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof, in the preparation of a composition or a formulation for the prevention and/or treatment of tumours. The compound of the present invention has a significant and excellent precise therapeutic effect on tumours with low expression or no expression and low activity or no activity of mitochondrial permeability transition pores, low expression or no expression and low activity or no activity of peptidyl prolyl isomerase F, low expression or no expression of NNMT genes, high expression of DNA methylase, high expression of UHRFI, high methylation levels of NNMT gene nucleotide sites, and/or high methylation levels of DNA CpG sites in the NNMT gene region.

##STR00001##